Shares of RIL were trading with mild cuts at Rs 2200.15 at 10.00 am, on Thursday. The counter had settled at Rs 2205.10 on Wednesday.A roadmap for 5G rollout, announcements on affordable 5G phone and low-cost laptop JioBook, arrangements with Saudi Aramco in O2C business and updates on the retail business would be on top of investor radar at the 44th Annual General Meeting (AGM) of Reliance Industries on Thursday.
The long to short ratio a measure of the number of bullish positions versus bearish of overseas investors in Nifty futures declined to 65% on Wednesday from the years high of 88.87% on May 27. This shows these investors are cutting their bullish bets on Nifty futures. Similarly, foreigners bought over 1.04 lakh index put options contracts since June16 compared to 41,867 index call options.
Shares of Aster DM Healthcare shed 5 per cent to Rs 151 on Wednesday but by 10.40 AM was trading at Rs 152.50. BSE Sensex was trading marginally lower at 52,547.37 at the same time. The scrip settled at Rs 158.20 in the previous session. Revenue from the operation jumped 5 per cent to Rs 2,390.88 crore in the quarter ended March 2021 from Rs 2,280.35 crore during the previous quarter ended March 2020.
So-called value stocks, expected to benefit from the economic recovery, have outperformed in 2021, while growth stocks, including major tech names like Apple and Nvidia, have rallied. Most of the 11 major S&P sector indexes rose, with consumer discretionary and energy among the biggest gainers. Unofficially, the Dow Jones Industrial Average rose 0.2% to end at 33,945.71 points, while the S&P 500 gained 0.51% to 4,246.46. The Nasdaq Composite climbed 0.79% to 14,253.27.
White Square Capital has told investors that it will shut its main fund and return capital this month after a review of its business model, the newspaper said, citing people familiar with the fund and a letter to investors
Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a licensc to Celgenes patents required to manufacture and sell (subject to USFDA approval) certain limited quantity of generic lenalidomide capsules in the US beginning on a confidential date that is sometime after March 2022.